Levonorgestrel News and Research

RSS

Bayer announces updated labels for drospirenone-containing COCs in the U.S.

In agreement with the U.S. Food and Drug Administration (FDA), Bayer HealthCare Pharmaceuticals Inc. today announced that it has updated the labels for its drospirenone-containing combination oral contraceptives (COCs) in the United States.

11 Apr 2012

Morning after pills difficult for teenagers to procure

Quite a few U.S. pharmacies may give teen girls incorrect information over the phone about whether they can get the morning-after pill. The pill is a form of emergency contraception taken within 72 hours after unprotected sex to prevent pregnancy without a prescription, a new study suggests.

27 Mar 2012

HHS: Plan B access will stay limited

The Department of Health and Human Services announced today that the morning-after pill, known as Plan B, will continue to be kept behind the pharmacy counter and girls younger than 17 will continue to need a prescription to obtain it.

8 Dec 2011

Watson introduces Amethia Lo and ethinyl estradiol tablets

Watson Pharmaceuticals, Inc. today announced that under a settlement with Teva Women's Health, Watson has launched Amethia Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE.

8 Dec 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

FDA: Study suggests increased risk of blood clots from drospirenone-containing contraceptives

On Monday, the United States Food and Drug Administration ("FDA") said its primary results of an agency funded study suggest a 1.5 fold increase risk of blood clots for women who use drospirenone-containing birth control products, such as Yaz and Yasmin.

28 Sep 2011

Watson Pharmaceuticals confirms SEASONIQUE patent challenge

Watson Pharmaceuticals, Inc., a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE and ethinyl estradiol.

18 Jun 2011

Safety of birth control pills under scrutiny

Bayer’s oral contraceptive pills are being reviewed by regulators after some studies suggested they may cause more blood clots than competing medicines.

5 Jun 2011

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

Sosei to introduce NorLevo oral emergency contraceptive in Japan

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, will launch its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, tomorrow 24 May, through the distribution network of its commercialization partner, ASKA Pharmaceutical Co., Ltd.

23 May 2011

Newer birth control pill raises risk of blood clots

Two human trials in the US and the UK including women from both populations showed that women taking newer forms of oral contraceptives, which include drosperinone, a synthetic version of the hormone progesterone, increased their risk of developing a blood clots by two or three times over those taking older birth control pills that rely on a different form of the hormone known as levonorgestrel.

26 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Bayer's birth control pills may increase risk of venous thromboembolism

The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's birth control pills Yaz and Yasmin, containing a new progestin drospirenone, carry up to triple the risk of serious blood clots over traditional pills containing the progestin levonorgestrel.

25 Apr 2011

Contraception drospirenone raises risk for blood clots

Two new drug safety studies conducted by researchers at Boston University School of Medicine (BUSM) provide strong evidence that women taking oral contraception with drospirenone have an increased risk of nonfatal venous thromboembolism, or blood clots, compared to women taking oral contraception with levonorgestrel.

21 Apr 2011

Drospirenone doesn't carry any risk of gall bladder disease

Drospirenone, the top-selling oral contraceptive marketed as Yaz or Yasmin in the U.S. and Canada, doesn't carry any more risk of gall bladder disease than the older generation of birth control pills, despite claims by some consumers and lawyers in both countries, according to a new study by University of British Columbia and Vancouver Coastal Health Research Institute researcher Mahyar Etminan.

19 Apr 2011

U.S. District Court rules in favor of Watson in generic SEASONIQUE patent infringement suit

Watson Pharmaceuticals, Inc., a leading integrated global pharmaceutical company, today confirmed that it has received a favorable decision from the U.S. Court of Appeals for the Federal Circuit related to its ongoing patent challenge in connection with Watson's Abbreviated New Drug Application seeking FDA approval to market a generic version of Teva Women's Health, Inc.'s SEASONIQUE and ethinyl estradiol.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Japan MHLW approves Sosei's NorLevo emergency contraceptive pill

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, was granted approval for its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, by the Japan Ministry of Health, Labour and Welfare (MHLW). NorLevo(R) has thus become the fist emergency contraceptive pill available in Japan.

23 Feb 2011

WomanCare Global expands product portfolio to include Roselle, Optinor

WomanCare Global is pleased to announce an expansion of their global product portfolio to include Roselle, a combined oral contraceptive (COC) pill containing 150 micrograms of levonorgestrel and 30 micrograms of ethinylestradiol and Optinor, a progesterone-only emergency contraception pill (ECP) containing 750 micrograms of levonorgestrel.

29 Nov 2010

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010